Synaptogenix Inc (SNPX)

[kld2]

Does it really have to be this hard? My god! Read! Read!

First pr of Ph2a data (Feb. 24):

The secondary objectives of the study were the preliminary evaluation of the efficacy of a single dose of bryostatin in the treatment of patients with AD, its pharmacokinetics and pharmacodynamics and to correlate the changes in PKCe with plasma levels of bryostatin and with improvement in cognitive function. The data regarding these secondary endpoints are still being reviewed.

Second pr with FINAL data (March 17)

An additional secondary objective of the study was the evaluation of efficacy following a single dose of bryostatin. As expected with a single dose of bryostatin, there was no measurable improvement in cognition in this mildly impaired patient population. It is important to note that in previous animal studies improvement of learning and memory was first observed following multiple doses of bryostatin.

I actually don't really care. It's just--isn't it obvious? Don't press releases count for something? I imagine, legally, they count for more than the Doc's words during a presentation. Go to Neurotrope's website. Click on Investors. Click on Press releases. Read. I hope it works. I hope you make millions. But I also hope you are sincere. I am not saying anything more than what the two press releases are saying about the Ph2a data in question. It's not like I'm making up anything. The first one was preliminary data. The second one--one month later--was final data after confirming preliminary data. What's that mean for Ph2b? I haven't the slightest idea.